FIELD: pharmacology.
SUBSTANCE: invention is a new application of the known N-2-adamantyl-hexamethyleneimine (hymantanum) hydrochloride as a means for opioid abstinence syndrome arresting.
EFFECT: decrease in the manifestation of somatic signs of opioid abstinence, prevents the development of mechanical allodynia in conditions of abrupt discontinuation of opioid intake, exhibits delayed analgesic activity.
3 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR REDUCING ALCOHOL MOTIVATION IN ALCOHOL DEPENDENCE | 2014 |
|
RU2582966C2 |
| AGENT FOR MANAGING ALCOHOL ABSTINENCE SYNDROME | 2012 |
|
RU2521226C2 |
| AGENT FOR ARRESTING AN ABSTINENT SYNDROME AT OPIOMANIA | 1996 |
|
RU2116084C1 |
| LOW-MOLECULAR MIMETIC BDNF AS AN AGENT FOR TREATING OPIOID DEPENDENCE | 2019 |
|
RU2707301C1 |
| MEDICATION FOR WITHDRAWAL SYNDROME MANAGEMENT IN OPIATE DEPENDENCE | 2012 |
|
RU2485954C1 |
| DIMERIC DIPEPTIDE MIMETIC BDNF AS AGENT FOR TREATING AND PREVENTING OPIOID ADDICTION | 2023 |
|
RU2823374C1 |
| AGENT FOR ABSTINENT SYNDROME ARRESTING AT OPIOMANIA | 1993 |
|
RU2083204C1 |
| ANALGESIC AGENT FOR VISCERAL PAIN MANAGEMENT | 2010 |
|
RU2429874C1 |
| ANALGESIC AGENT AND THERAPY OF PAIN SYNDROME OF VARIOUS AETIOLOGIES BY USING SAID AGENT | 2007 |
|
RU2367432C2 |
| COMPOSITION FOR TERMINATION OF OPIATE ABSTINENT SYNDROME MANIFESTATIONS | 2007 |
|
RU2323725C1 |
